The NCCN Affiliate Research Project (ARP), developed by the NCCN Oncology Research Program (ORP), has qualified its first seven affiliate sites from the Fox Chase Cancer Center Partners Program, the Seattle Cancer Care Alliance Affiliate Network, and University of Alabama at Birmingham Cancer Care Network. The newly qualified ARP community sites are:
The mission of the NCCN ARP is to improve patient outcomes and to advance medical science through clinical research conducted through collaboration among the National Comprehensive Cancer Network® (NCCN®), the 21 NCCN Member Institutions, and their community-based affiliate networks. The NCCN ARP plans to approve a minimum of three additional sites this year to potentially support more than 50 actively enrolling ORP trials.
The NCCN ORP is organized to obtain funding to support scientifically meritorious research projects at NCCN Member Institutions. Policies and standards for the program were set by the NCCN Investigator Steering Committee, a group comprised of senior research physicians appointed by each NCCN Member Institution. To date, the NCCN ORP has received more than $36 million in research grants from pharmaceutical and biotech companies to support investigator-initiated trials including, but not limited to, evaluation of innovative regimens, mechanism of action, and exploration of extended uses for specific agents.
Affiliate sites of the ORP will have access to new and innovative cancer drugs for their patients in collaboration with NCCN Member Institutions, and Principal Investigators of NCCN-funded studies will have access to NCCN-qualified community sites. "We are delighted with the addition of community affiliates. The qualification of these sites will not only enhance studies through the diversification of patient cohorts, but also expedite accrual so that important research questions can be answered in a timely manner," said Diane Paul, MS, RN, Vice President of the Oncology Research Program.